24 - 25 january: BioSimilars Forum Conference in London, participation of Béatrice Holtz.

12 - 15   october 2011 : 82nd PTMG (Pharmaceutical Trademark Group) Conference in Prague, participation of Bé©atrice Daubin and of Grégoire Goussu .

2-3 december 2010 : Pan-European Intellectual Property Summit in Brussels (Belgium), participation of Serge Binn.

13-15 November 2009 : Conference of the Intellectual Property International in Seoul, participation of Philippe Blot and of Simone Kling. 11-14 November 2009 : INTA, annual congress in Miami, participation of Catherine Levalet. 10-15 October 2009: AIPPI Forum and Executive Committee in Buenos Aires, with the participation of...

12-15 November 2008: INTA Mid-Year Meeting in Boca Raton with the participation of Catherine Levalet 01-04 October 2008: 77th PTMG Conference in Istanbul with the participation of Beatrice Daubin 06-11 September 2008: 41st AIPPI Congress in Boston with the participation of Gérard Myon and David Millet 18-21 June 2008: ECTA...

7-10 November 2007: INTA Mid-Year Meeting in Orlando, with the participation of Catherine Levalet 4-11 November 2007: FICPI Forum and Executive Committee meeting in Seville, with the participation of Michel Moncheny, Jean-Pierre Colas and Philippe Blot 4-10 October 2007: AIPPI Forum and Executive Committee meeting in Singapore,...

To fulfil growing demand from local clients, LAVOIX has opened a new office in Rennes. This move will reinforce LAVOIX’s regional coverage, particularly for companies who wish to expand into Brittany, complementing existing regional offices in Lyon, Toulouse and Clermont-Ferrand. 'The opening of our Rennes office...

The journal M.I.P (Managing Intellectual Property) has recently published its yearly ranking of firms filing international (PCT) patent applications. LAVOIX is the leading filer of PCT applications in France, with 345 applications filed in 2011. LAVOIX was likewise ranked first in 2010, with 317 PCT filings....

LAVOIX won the IP award for France for 2011, presented by Managing IP, the leading international magazine in the area of IP, on Wednesday, 6 April in London. The presentation of this award follows a decision made on the basis of a questionnaire sent to companies, lawyers, patent and trademark attorneys, and specialist...

From January, 24th, 2011 LAVOIX Clermont-Ferrand's adress will be: 3 rue Kepler 63100 Clermont Ferrand Tél. : 33 (0)4 73 36 04 09 Fax : 33 (0)4 73 37 54 74 e-mail : clermont-ferrand@lavoix.eu

Both firms pursue their continuing sharing and common development, with JP COLAS' clients, suppliers, and partners becoming those of LAVOIX as from 1st october 2010. " This merger completes the integration of the Cabinet JP COLAS in LAVOIX initiated since 2007 and will enable us to continue to strengthen our relationship...

Managing Intellectual Property (MIP) is a reference magazine of Intellectual and Industrial Property; it recently revealed its yearly "World IP Survey" and its Top PCT filing firms. LAVOIX is named first French, third European and twentieth worldwide PCT filing firm, according to the MIP survey. "This award...

LAVOIX performed the due diligence IP concerning the acquisition of CellVir by the pharamceutical company Pharma Omnium International (POI). CellVir is a biotechnological company established in 2006 and based at the Institut Cochin of Paris. Pharma Omnium, held by Weinberg Capital Partners, is thus reinforced in the...

In order to reinforce the expertise of our Chemical and Life Science Department in the pharmaceutical sector, we welcome Elisabeth Thouret-Lemaître as a consultant. Elisabeth has worked throughout her whole career in this sector and held the position of patent director of a multinational pharmaceutical company. She handles...

Grégoire Goussu joins Lavoix Avocats, Intellectual Property specialized law firm. Grégoire Goussu began his career at Gide Loyrette Nouel in 1990 and he became a partner of the IP/IT department in 2001. On september 2008, he joined the litigation department of the International law firm Proskauer Rose where he headed the Paris...

LAVOIX Munich expands and moves to new premises Starting from January 1st, 2010, our new contact details are: Bayerstrasse 85a 80335 Munich - Germany Tél. : 49 (0)89 452 05 870 Fax : 49 (0)89 452 05 8729 e-mail : munich@lavoix.eu

Dear clients, dear colleagues, We are pleased to inform you that LAVOIX has been approved to the ISO 9001 - 2008 standard. This certification applies to all the IP attorney activities of LAVOIX in France, Europe and worldwide. It is the result of a two-year global and continuous process, which aims at improving the LAVOIX...

LAVOIX Avocats advised Purple Labs in its' acquisition of the mobile applications suite and software engineering team of Sagem Wireless. Cyrille Amar, partner, lead the negotiation of a multi-product license agreement (€ 52 million). Others advisors : Eversheds, EY-Law, Preuilh.Vidonne, Jones Day.

Binn & Associés join LAVOIX patent and trademark attorneys to create the largest full service IP practice in France. LAVOIX, a leading patent and trademark attorney firm in France, is teaming up with the IP law firm Binn & Associés to create the largest full-service Intellectual Property practice in France. Binn &...

Lavoix won the IP prosecution award for France for 2008, presented by Managing IP, the leading international magazine in the area of IP, on Wednesday, 9 April in London. The presentation of this award follows a decision made on the basis of a questionnaire sent to companies, lawyers, patent and trademark attorneys, and...

Lavoix links up with the firm of JP Colas and reinforces its position as No. 2 on the French industrial property attorney market

1.1 Article 112a EPC allows, under certain specific circumstances, a party adversely affected by a decision of a Board of Appeal to have the decision reviewed by the Enlarged Board of Appeals. Article 112a was inserted in the EPC2000 and came into effect on December 13, 2007. 1.2 According to A112a(2)EPC, the...

Article 11 of the Rules relating to Fees of the European Patent Convention sets out the conditions under which a full or 75% refund of the examination fee will be made. According to this Article, the examination fee shall be refunded: (a) in full if the European patent application is withdrawn, refused or...

Legal context According to the European Patent Convention, Article 69(1), the extent of the protection conferred by a European patent shall be determined by the claims. Nevertheless, the description and drawings shall be used to interpret the claims. Further, in German case law in litigation proceedings a...

1. In cases where the European Patent Office (EPO) has acted as International Search Authority (ISA) or International Preliminary Examining Authority (IPEA), the applicant is invited by a communication under Rule 161 EPC to correct deficiencies noted in the Written Opinion of the ISA, the International Preliminary Examination...

Legal context Applications for a German patent or utility model do not necessarily have to be filed in German. Indeed, the German Patent and Trademark Office (GPTO) accepts such applications in any language provided the applicant files a German translation thereof within three months from the filing date. If no German...

In a recent decision (Novartis c. Actavis, TGI Paris, 28 January 2011), le Tribunal de Grande Instance of Paris granted a preliminary injunction preventing the marketing of pharmaceutical compositions containing valsartan and hydrochlorthiazide (HCTZ), considering that marketing of such compositions would infringe the SPC for...

Rule 161 EPC was introduced by the European Patent Office (EPO) in the attempt to accelerate the prosecution of Euro-PCT applications in the early stage. For applications where the EPO acted as International Searching Authority (ISA), Rule 161(1) EPC requires the applicant to respond early in the proceedings to any...

On 12th May, the Enlarged Board of Appeal delivered its opinion G3/08, dealing with the patentability of programs for computers. If you have any specific questions with regards to these matters, please let us know, we would be happy to give you additional information. To read this article, click on the link below

26th February 2010, Last week, the Enlarged Board of Appeals of the EPO issued three decisions: G1/07 and G2/08 dealing with exceptions to patentability in the medical field, G4/08 with issues relating to the language of proceedings. Please find attached our analysis of these decisions, that you will hopefully find useful. If...

In a recent decision dated 28th September 2010, the French first instance Paris Court has considered whether a "second medical use" claim directed to an administration dose would be admissible. The claim of the European patent in suit was worded according to the Swiss-type claim format and recited the treatment of...

A recent case found that generic pharmaceutical company can use the name of a branded drug in comparative advertising in France. Philips Lods of Lavoix examines how branded pharmaceutical companies can defend themselves. Clik on the link below to read the article.

Standard setting organisations aim to balance the needs of patent holders and consumers. What is the effect of the FRAND undertaking in practice ? Article published in July 2009 in the "IP Focus 2009 Europe" of Managing Intellectual Property n°191. Writers: Cyrille Amar and Jean-marc Puech. To read this article, click on the...

A year on from the implementation of EPC 2000, those seeking to lodge claims to protect further medical use should be aware of the dangers of continuing former practice. Article paru dans le numéro de Novembre-Décembre 2008 du magazine "World Intellectual Property Review". Rédacteurs : Lionel Vial, Sonia Dias and...

Analyse of the patent exemption provided by Directive EC 2004/27 and summary of the current status of its implementation in each of the member states. Article published in "Life Sciences Intellectual Property Review 2008". Writers : Stéphanie Michiels and Béatrice Holtz. To read this article, click on the link below

Changes to European patent law have brought an end to the need for Swiss-type claims. What does replace them? Article published in June 2008 in the n°180 of Managing Intellectual Property "Patent pioneers. Inventions that built the Biotech Industry". Writers: Béatrice Holtz and Lionel Vial. To read this article, click on the...

French law has recently brought in the Legal Protection of Biotechnological Inventions European Directive. Its implementation has caused surprising uncertainty about patent protection of isolated gene sequences in France. Article published in February 2008 in the n°176 of Managing Intellectual Property "The leading patent firms...

Patent infringement cases generally rely on the issue of claim construction. The crucial question facing the Courts is whether a specific feature of the claims is limited to the actual recitation of the claims or whether it actually may be extended to other embodiments. The French Courts tended to be reluctant to consider...

A revised version of the European Patent Convention (EPC 2000) will enter into force on 13 December 2007. Amendments will affect many aspects of the European proceedings, the followings being in our view of particular relevance to the practitioners and applicants: Filing of European patent applications The requirements for the...